Quell Therapeutics
PrivateLast Round
Strategic
Jun 9, 2023
Est. Valuation
$34.09M
Total Funding Raised
$405.4M
Company Overview
Quell Therapeutics is a biotechnology company that develops engineered T-regulatory (Treg) cell therapies to treat severe immune-mediated and inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Quell Therapeutics Comparables
Compare Quell Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Sonoma Biotherapeutics | 88% | |
| GentiBio | 84% | |
| ActiTrexx GmbH | 83% |
Quell Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Jun 9, 2023 | ||||
| Series B | Nov 29, 2021 | ||||
| Series A Extension | Feb 11, 2021 | ||||
| Series A | May 20, 2019 | ||||
| Series A | Mar 29, 2019 |
Quell Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Janus Henderson Group | Series B |
| SV Health Investors | Series B |
| Syncona | Series B, Series A, Series A Extension |
| Ridgeback Capital | Series B |
| Future Fund | Series B |
| Fidelity Management & Research Company | Series B |
| British Patient Capital | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 25, 2025
Presenting data at ACR Convergence 2025.
- Oct 25, 2025
Will present data for QEL-005 CAR-Treg cell therapy at ACR Convergence 2025.
Quell Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Quell Therapeutics's valuation, stock price, and market status.
Is Quell a public or private company?
Quell is a private company.
What is the current stock price of Quell?
Quell is a private company with no public stock price. No recent secondary market data is available.
How much is Quell worth (valuation)?
Quell's valuation is estimated at $34.1M based on funding round data.
Can I buy Quell stock?
Quell shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Quell's last funding round?
Quell's most recent funding round was Strategic on March 29, 2019.
Who are the main investors in Quell?
Key investors in Quell include SV Health Investors, Syncona, Ridgeback Capital, Fidelity Management & Research Company, Albion Capital.
Will Quell IPO soon?
No public IPO plans have been announced for Quell.
How can I track Quell secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Quell's secondary market activity and sign up for updates.